Press Releases

Date Title and Summary Additional Formats
Toggle Summary Autism Spectrum Disorder, Fragile X Syndrome, and 22q11.2 Deletion Syndrome Share a Constellation of Sociobehavioral Symptoms
- Preliminary Evidence Shows that CBD May Prove to be Effective in Managing the Spectrum of Behavioral Symptoms Associated with these Conditions – - New Data Presented Today at the Society for the Study of Behavioural Phenotypes (SSBP) Research Symposium - DEVON, Pa. , Sept.
View HTML
Toggle Summary Cannabis and Cannabinoid Research Publishes Data Demonstrating the Degradation of Cannabidiol to Psychoactive Cannabinoids when Exposed to Simulated Gastric Fluid
Transdermal CBD Gel ZYN002 has the potential to avoid bioconversion to psychoactive THC by bypassing the gastrointestinal tract DEVON, Pa. , April 12, 2016 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), a specialty pharmaceutical company dedicated to the development of innovative
View HTML
Toggle Summary New Caregiver-Reported Data Further Validate the Use of the Aberrant Behavior Checklist Community: FXS Specific (ABC-CFXS) Subscales to Assess Core Behavioral Symptoms of Fragile X Syndrome (FXS)
- Ninety Percent of Interviewed Caregivers Reported Social Avoidant, Irritability, and Socially Lethargic Behaviors in their Children with FXS - - New Data Presented Today at the Society for the Study of Behavioural Phenotypes (SSBP) Research Symposium - DEVON, Pa. , Sept.
View HTML
Toggle Summary Zynerba Files Registration Statement for Proposed Initial Public Offering of Common Stock
Devon, PA, June 30, 2015 – Zynerba Pharmaceuticals, Inc. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to the proposed initial public offering of its common stock.
View HTML
Toggle Summary Zynerba Pharmaceuticals Achieves Target Enrollment in Exploratory Phase 2 Trial of ZYN002 in Fragile X Syndrome
- Top-line data from this study remains on track to report in September 2017 - DEVON, Pa. , June 08, 2017 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative transdermal synthetic
View HTML
Toggle Summary Zynerba Pharmaceuticals Added to Russell 2000® and 3000® Indexes
DEVON, Pa. , July 01, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that the Company will be added as a member of the U.S.
View HTML
Toggle Summary Zynerba Pharmaceuticals Added to the Russell 3000® Index
DEVON, Pa. , June 26, 2017 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative transdermal synthetic cannabinoid treatments, today announced that it has been added to the Russell
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Closing of Its Initial Public Offering and Exercise in Full of Option to Purchase Additional Shares
DEVON, Pa. , Aug. 10, 2015 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), announced today the closing of its initial public offering of 3,450,000 shares of common stock at a public offering price of $14.00 per share, before underwriting discounts, which includes the exercise in
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Completion of Enrollment for ZYN002 in Two Phase 2 Clinical Trials for Epilepsy and Osteoarthritis
Top-line data for both Phase 2 clinical trials remains on track to report in July/August 2017 DEVON, Pa. , March 13, 2017 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Dosing of First Patients in Phase 2 STAR 1 Clinical Study of ZYN002 CBD Gel in Adult Epilepsy Patients with Refractory Focal Seizures
DEVON, Pa. , Aug. 01, 2016 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that the first patients have been dosed in the
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
DEVON, Pa. , Feb. 09, 2017 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that the underwriters of its previously announced
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Initiation of Phase 2 Trial of Zygel™ in 22q11.2 Deletion Syndrome
Topline Data from the INSPIRE Trial Expected in the First Half 2020 DEVON, Pa. , May 29, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders,
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Initiation of STAR 2 Open-Label Extension Clinical Trial for ZYN002 CBD Gel in Adult Refractory Epilepsy Patients
DEVON, Pa. , Nov. 02, 2016 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced the enrollment of the first patients into the STAR 2
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Initiation of the FAB-C Exploratory Phase 2 Clinical Trial of ZYN002 CBD Gel in Patients with Fragile X Syndrome
DEVON, Pa. , Jan. 03, 2017 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that it has initiated the FAB-C (Treatment of F
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces New FAB-C Phase 2 Open-Label Data in Patients with Fragile X Syndrome
- Significant Improvements in Behavioral Symptoms Observed in Patients and Sustained through 38 Weeks of Treatment with ZYN002 - - Presentation Today at the 16 th NFXF International Fragile X Conference - FAB-C Week 38 - Extension Phase Data: ADAMS Mean Percent Improvement From Baseline FAB-C Week
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces New ZYN002 Data from STAR 1 and STAR 2 Studies in Patients with Focal Seizures at the 2017 Annual Meeting of the American Epilepsy Society (AES)
- Clinically Meaningful Median Reduction in Seizures Compared to Baseline of 48% to 65% Achieved with Continued ZYN002 Treatment in STAR 2 Extension Study – Median Percent Change in Seizure Rates at Week 12 (STAR 1) and Month 3 and 6 (STAR 2) - Data Help Clarify Protocol Design for Planned ZYN002
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces New ZYN002 Data from STAR 1 and STAR 2 Studies in Patients with Focal Seizures at the 2017 Annual Meeting of the American Epilepsy Society (AES)
- Clinically Meaningful Median Reduction in Seizures Compared to Baseline of 48% to 65% Achieved with Continued ZYN002 Treatment in STAR 2 Extension Study – Median Percent Change in Seizure Rates at Week 12 (STAR 1) and Month 3 and 6 (STAR 2) - Data Help Clarify Protocol Design for Planned ZYN002
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Oral Presentation of ZYN002 Data at the 16th NFXF International Fragile X Conference in July 2018
DEVON, Pa. , April 23, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare and near-rare
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Positive Initial Results From ZYN002 CBD Gel Phase 1 Single Rising Dose Trial and Initiation of Phase 1 Multiple Rising Dose Trial
DEVON, Pa. , Jan. 06, 2016 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ: ZYNE), a specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced positive initial safety results from its Phase 1 single rising
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Positive Meeting with U.S. Food and Drug Administration and Plans to Conduct a Single Pivotal Study of ZYN002 in Fragile X Syndrome to Support an NDA Filing
Company Expects to Initiate Pivotal Study Mid-Year 2018 and Deliver Top-line Data in 2019 DEVON, Pa. , March 05, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Positive Top Line Data from BELIEVE 1 Open Label Phase 2 Study of Zygel™ in Developmental and Epileptic Encephalopathies (DEE)
- Study Achieves a 44% Median Seizure Reduction in Focal Impaired Awareness (Complex Partial) and Convulsive Seizures in DEE Patients by Month Two; Reductions were Sustained through Month Six of Treatment with Zygel - - At Least 42% of these Patients Experienced a ≥50% Improvement from Month Two
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Positive Top Line Results from ZYN002 CBD Gel Phase 1 Multiple Rising Dose Trial and Initiation of Phase 2 Study in Adult Epilepsy Patients with Refractory Focal Seizures
Two additional Phase 2 clinical trials are expected to begin in 2H16 in patients with Osteoarthritis and Fragile X Syndrome DEVON, Pa. , June 27, 2016 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), a specialty pharmaceutical company dedicated to the development of innovative
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Positive Top Line Results in ZYN002 Open Label Phase 2 FAB-C Study in Children with Fragile X Syndrome
ZYN002 successfully met the primary endpoint and showed clinically meaningful improvements Zynerba to host conference call and webcast today, September 28 at 8:30 am ET DEVON, Pa. , Sept. 28, 2017 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), a clinical-stage specialty
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Poster Presentation at the 2017 Annual Meeting of the American Epilepsy Society (AES)
DEVON, Pa. , Nov. 21, 2017 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments, today announced the acceptance and
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Poster Presentation at the 2018 Annual Meeting of the American Academy of Neurology (AAN)
DEVON, Pa. , March 22, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare and near-rare
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Poster Presentations at the 22nd Society for the Study of Behavioural Phenotypes (SSBP) Symposium
DEVON, Pa. , Aug. 29, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the acceptance and presentation details of two posters
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Pricing of Its Initial Public Offering
DEVON, Pa. , Aug. 4, 2015 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. , announced today the pricing of its initial public offering of 3 million shares of common stock at a public offering price of $14.00 per share, before underwriting discounts.
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Pricing of Public Offering of Common Stock
DEVON, Pa. , Jan. 19, 2017 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced the pricing of an underwritten public offering of
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Pricing of Public Offering of Common Stock
DEVON, Pa. , July 20, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) today announced the pricing of an underwritten public offering of 4,062,500 shares of its common stock at a price of $8.00 per share, for a gross deal size of $32.5 million , before deducting underwriting
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Proposed Public Offering of Common Stock
DEVON, Pa. , Jan. 18, 2017 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that it intends to offer and sell, subject to market
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Proposed Public Offering of Common Stock
DEVON, Pa. , July 19, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering.  All of the shares to be sold in the offering will be offered by
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Publication of Preclinical Data in Neuropsychopharmacology Demonstrating Effect of Cannabidiol Gel Treatment in Reduction of Relapse in an Addiction Model
Results show effect of transdermally-delivered cannabidiol (ZYN002) in an animal model of drug relapse and extend its therapeutic potential to relapse prevention in substance use disorders DEVON, Pa. , March 26, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc.
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Publication of Zygel™ (ZYN002) 12-week Open Label Fragile X Syndrome Data in the Journal of Neurodevelopmental Disorders
DEVON, Pa. , Aug. 06, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the publication of data from the Phase 2 FAB-C
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Sustained Improvements in Emotional and Behavioral Symptoms of Fragile X Syndrome through 12 Months of Treatment with ZYN002
- Patients Experienced a 77% Improvement in Aberrant Behaviors Associated with Social Avoidance Compared to Baseline after One Year of ZYN002 Treatment - FAB0C Month 12: ADAMS Percent Improvement from Baseline with ZYN002 FAB-C Month 12: ABC-CFXS Percent Improvement from Baseline with ZYN002 -
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces that Results from Phase 2 STOP Trial Support Continued Development of ZYN002 in Osteoarthritis
Zynerba to host conference call and webcast today, August 14 at 8:30 am ET DEVON, Pa. , Aug. 14, 2017 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative transdermal
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Top Line Results from ZYN001 THC-Prodrug Patch Phase 1 Study
DEVON, Pa. , July 05, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, announced top line results from a Phase 1 clinical program studying
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Top-Line Results from Phase 2 STAR 1 Trial of ZYN002 in Adult Epilepsy Patients with Focal Seizures
Company to host conference call and webcast today, August 7 at 8:30am ET DEVON, Pa. , Aug. 07, 2017 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative transdermal
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces Twelve Month ZYN002 Data from STAR 2 Study in Patients with Focal Seizures at the 2018 Annual Meeting of the American Academy of Neurology (AAN)
Continued Improvement in Seizure Control Seen in Adult Refractory Focal Seizure Patients Receiving ZYN002 through 12 Months of Open Label Exposure Median Change in Seizure Rates at Months 3, 6, 9 and 12: All ZYN002-treated patients in STAR 2 Median Change in Seizure Rates at Months 3, 6, 9 and 12:
View HTML
Toggle Summary Zynerba Pharmaceuticals Announces ZYN002 Granted Orphan Drug Designation for Fragile X Syndrome
DEVON, Pa. , Feb. 25, 2016 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by  Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), please note that in the second paragraph of the release, the quote should end with "in the second half of this year," instead of "by the end of
View HTML
Toggle Summary Zynerba Pharmaceuticals Appoints John P. Butler to Board of Directors
DEVON, Pa. , April 16, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare and near-rare
View HTML
Toggle Summary Zynerba Pharmaceuticals Appoints New Leadership Team: Armando Anido Named Chairman and CEO, Terri Sebree Named President
RADNOR, PA – (PR Newswire – October 1, 2014) Zynerba Pharmaceuticals, Inc., a specialty pharmaceutical company dedicated to the development of innovative transdermal cannabinoid treatments, today named two leading industry veterans with track records of success in patch and gel transdermal delivery
View HTML
Toggle Summary Zynerba Pharmaceuticals Appoints Pamela Stephenson to Board of Directors
DEVON, Pa. , Feb. 20, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the appointment of Pamela Stephenson to its Board of
View HTML
Toggle Summary Zynerba Pharmaceuticals Appoints Richard A. Baron VP and CFO
RADNOR, PA – (PR Newswire – January 5, 2015) Zynerba Pharmaceuticals, Inc., a specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, announced that the appointment of Richard A. Baron as vice president and chief financial officer
View HTML
Toggle Summary Zynerba Pharmaceuticals Appoints Warren D. Cooper Lead Independent Director
DEVON, Pa. , Nov. 16, 2015 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), a specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced the Company's Board of Directors has appointed Warren Cooper, MB,
View HTML
Toggle Summary Zynerba Pharmaceuticals Builds Management Team
RADNOR, PA – (PR Newswire – October 1, 2014) Zynerba Pharmaceuticals, Inc., a specialty pharmaceutical company dedicated to the development of innovative transdermal cannabinoid treatments, today named three seasoned pharmaceutical executives to its management team.
View HTML
Toggle Summary Zynerba Pharmaceuticals Builds Out Board of Directors
High-Caliber Appointees Offer Track Record of Success in Building Innovative Pharmaceutical Companies as Company Closes IPO DEVON, Pa. , Aug. 6, 2015 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), announced today that it has appointed six new members of its board of directors.
View HTML
Toggle Summary Zynerba Pharmaceuticals Initiates CONNECT-FX, a Pivotal Clinical Trial of ZYN002 in Fragile X Syndrome
Study will Evaluate the Efficacy and Safety of Transdermally-Delivered Cannabidiol (CBD) in Children and Adolescents with Fragile X Syndrome Top Line Results Expected in Second Half of 2019 Zynerba to host conference call and webcast today at 8:30 am DEVON, Pa.
View HTML
Toggle Summary Zynerba Pharmaceuticals Initiates Open-Label Phase 2 Trial of ZYN002 in Developmental and Epileptic Encephalopathies (DEE)
DEVON, Pa. , April 10, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare and near-rare
View HTML
Toggle Summary Zynerba Pharmaceuticals Initiates Phase 1 Clinical Trial for ZYN002 CBD Gel
First and Only Patent-Protected Synthetic CBD Gel Being Studied in Refractory Epilepsy, Fragile X Syndrome and Osteoarthritis DEVON, Pa. , Oct. 20, 2015 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), a specialty pharmaceutical company dedicated to the development of innovative
View HTML
Toggle Summary Zynerba Pharmaceuticals Initiates Phase 2 Trial of Zygel™ in Autism Spectrum Disorder
- Topline Data from BRIGHT Study Expected in the First Half 2020 - - Company Selects Zygel™ as Brand Name for ZYN002 CBD Transdermal Gel - DEVON, Pa. , March 07, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal
View HTML
Toggle Summary Zynerba Pharmaceuticals Initiates ZYN001 Phase 1 Clinical Program
Phase 1 results will inform potential Phase 2 studies in patients with fibromyalgia and neuropathic pain, planned to start in 2H17 Study includes single rising dose and multiple rising dose evaluations DEVON, Pa. , June 26, 2017 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc.
View HTML
Toggle Summary Zynerba Pharmaceuticals Launches Phase 2 Clinical Trial of ZYN002 CBD Gel for Treatment of Osteoarthritis
DEVON, Pa. , Sept. 06, 2016 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that it has initiated a Phase 2 clinical trial,
View HTML
Toggle Summary Zynerba Pharmaceuticals Mourns Passing of Director Cynthia A. Rask
DEVON, Pa. , July 28, 2017 (GLOBE NEWSWIRE) -- It is with great sadness that Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) mourns the death of Director Cynthia A. Rask , M.D. “All of the Zynerba family are mourning the loss of Cynthia, our friend and Director,” said Armando Anido , Chairman and Chief
View HTML
Toggle Summary Zynerba Pharmaceuticals Provides 2018 Clinical and Corporate Update
 - Focusing Strategy on Rare and Near-Rare Neurological and Psychiatric Disorders - - Pediatric Neurologist Liza Squires, M.D. Joins as Chief Medical Officer - - Conference Call to be Held at 8:30 AM Tomorrow , January 4, 2018 - DEVON, Pa. , Jan. 03, 2018 (GLOBE NEWSWIRE) --   Zynerba
View HTML
Toggle Summary Zynerba Pharmaceuticals Provides Clinical Update and Announces Two New Clinical Indications
- Company Will Focus on Four Childhood Neuropsychiatric Disorders: FXS, DEE, Autism Spectrum Disorder and 22q11.2 Deletion Syndrome - - Cash Runway Now Extends into the Second Half of 2020 - - Conference Call to be Held Today at 8:30 am Eastern Time - DEVON, Pa. , Dec.
View HTML
Toggle Summary Zynerba Pharmaceuticals Raises $13 Million to Develop First and Only Transdermal Cannabinoid Therapies
RADNOR, PA – (PR Newswire – October 15, 2014) Zynerba Pharmaceuticals, Inc., a specialty pharmaceutical company dedicated to the development of innovative transdermal cannabinoid treatments, today announced the successful closing of $13 million in funding.
View HTML
Toggle Summary Zynerba Pharmaceuticals Receives Fast Track Designation for Zygel™ for the Treatment of Behavioral Symptoms Associated with Fragile X Syndrome (FXS)
- Designation Facilitates and Expedites Development of Drugs for Patients with Serious Unmet Medical Needs - - Enrollment Progressing in Pivotal CONNECT-FX Trial of Zygel in FXS, with Data Expected in the Second Half of 2019 - DEVON, Pa. , May 06, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals,
View HTML
Toggle Summary Zynerba Pharmaceuticals Receives New U.S. Patent for Treatment of Autism Spectrum Disorder with Cannabidiol
DEVON, Pa. , June 11, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that the U.S.
View HTML
Toggle Summary Zynerba Pharmaceuticals Receives New U.S. Patent for Treatment of Fragile X Syndrome with Cannabidiol
DEVON, Pa. , Feb. 26, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that the U.S.
View HTML
Toggle Summary Zynerba Pharmaceuticals Reports First Quarter 2016 Financial Results and Operational Highlights
DEVON, Pa. , May 12, 2016 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), a specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today reported financial results for the quarter ended March 31, 2016, and provided
View HTML
Toggle Summary Zynerba Pharmaceuticals Reports First Quarter 2017 Financial Results and Operational Highlights
DEVON, Pa. , May 09, 2017 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative transdermal synthetic cannabinoid treatments, today reported financial results for the first quarter
View HTML
Toggle Summary Zynerba Pharmaceuticals Reports First Quarter 2018 Financial Results and Operational Highlights
DEVON, Pa. , May 08, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare and near-rare
View HTML
Toggle Summary Zynerba Pharmaceuticals Reports First Quarter 2019 Financial Results and Operational Highlights
DEVON, Pa. , May 08, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today reported financial results for the first quarter ended March 31,
View HTML
Toggle Summary Zynerba Pharmaceuticals Reports Fourth Quarter and Year End 2015 Financial Results and Operational Highlights
Positive Initial Phase 1 ZYN002 Single Rising Dose Results Reported; Phase 1 Multiple Rising Dose Trial Underway FDA Grants ZYN002 Orphan-Drug Designation for Fragile X Syndrome Three ZYN002 Phase 2a Trials Planned for Initiation in Second Half 2016 DEVON, Pa.
View HTML
Toggle Summary Zynerba Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial Results and Operational Highlights
Conference call to be held today at 8:30 am ET DEVON, Pa. , March 27, 2017 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative transdermal synthetic cannabinoid treatments, today
View HTML
Toggle Summary Zynerba Pharmaceuticals Reports Fourth Quarter and Year End 2017 Financial Results and Operational Highlights
DEVON, Pa. , March 12, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare and near-rare
View HTML
Toggle Summary Zynerba Pharmaceuticals Reports Fourth Quarter and Year End 2018 Financial Results and Operational Highlights
DEVON, Pa. , March 11, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today reported financial results for the fourth quarter and year
View HTML
Toggle Summary Zynerba Pharmaceuticals Reports Inducement Grant to New Chief Financial Officer
DEVON, Pa. , Sept. 13, 2016 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that the Company’s Board of Directors granted
View HTML
Toggle Summary Zynerba Pharmaceuticals Reports Second Quarter 2016 Financial Results and Organizational Changes
Jim Fickenscher will assume role as Chief Financial Officer, VP, Corporate Development Dr. Nancy Tich appointed VP, Clinical, in a newly created position DEVON, Pa. , Aug. 11, 2016 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company
View HTML
Toggle Summary Zynerba Pharmaceuticals Reports Second Quarter 2017 Financial Results and Operational Highlights
Top-line Phase 2 results for STAR 1 trial in epilepsy and STOP trial in osteoarthritis remain on track for reporting in August 2017 DEVON, Pa. , Aug. 01, 2017 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to developing
View HTML
Toggle Summary Zynerba Pharmaceuticals Reports Second Quarter 2018 Financial Results and Operational Highlights
Zynerba to host conference call and webcast today at 8:30 am DEVON, Pa. , Aug. 02, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today
View HTML
Toggle Summary Zynerba Pharmaceuticals Reports Second Quarter 2019 Financial Results and Operational Highlights
DEVON, Pa. , Aug. 06, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today reported financial results for the second quarter ended June 30,
View HTML
Toggle Summary Zynerba Pharmaceuticals Reports Third Quarter 2015 Financial Results and Operational Highlights
Successful IPO, Initiation of Phase 1 for ZYN002 CBD Gel and Leadership Team Build-Out DEVON, Pa. , Nov. 11, 2015 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), a specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid
View HTML
Toggle Summary Zynerba Pharmaceuticals Reports Third Quarter 2016 Financial Results and Operational Highlights
DEVON, Pa. , Nov. 14, 2016 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today reported financial results for the third quarter
View HTML
Toggle Summary Zynerba Pharmaceuticals Reports Third Quarter 2017 Financial Results and Operational Highlights
DEVON, Pa. , Nov. 14, 2017 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments, today reported financial results for
View HTML
Toggle Summary Zynerba Pharmaceuticals Reports Third Quarter 2018 Financial Results and Operational Highlights
DEVON, Pa. , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today reported financial results for the third quarter ended September
View HTML
Toggle Summary Zynerba Pharmaceuticals to Highlight Data for ZYN002 CBD Gel at the 70th Annual Meeting of the American Epilepsy Society
DEVON, Pa. , Nov. 28, 2016 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that two posters relating to ZYN002, its
View HTML
Toggle Summary Zynerba Pharmaceuticals to Host Clinical Research Day on December 15, 2016 to Discuss the Role of ZYN002 CBD Gel in Multiple Diseases
Speakers include world-renowned physicians Meeting to begin at 8:00 am ET ; webcast will be available DEVON, Pa. , Dec. 08, 2016 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal
View HTML
Toggle Summary Zynerba Pharmaceuticals to Host Conference Call to Provide Second Quarter 2018 Business Update
DEVON, Pa. , July 31, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, will host a conference call at 8:30 am EDT on Thursday August 2, 2018
View HTML
Toggle Summary Zynerba Pharmaceuticals to Participate in Upcoming Investor Conferences
DEVON, Pa. , Sept. 06, 2017 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative transdermal pharmaceutically-produced cannabinoid treatments, today announced that Armando Anido ,
View HTML
Toggle Summary Zynerba Pharmaceuticals to Participate in Upcoming Investor Conferences
DEVON, Pa. , March 01, 2017 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that Armando Anido , Chairman and Chief Executive
View HTML
Toggle Summary Zynerba Pharmaceuticals to Participate in Upcoming Investor Conferences
DEVON, Pa. , Sept. 06, 2016 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that the Company will present at various upcoming investor
View HTML
Toggle Summary Zynerba Pharmaceuticals to Participate in Upcoming Investor Conferences
DEVON, Pa. , Nov. 21, 2016 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that Armando Anido , Chairman and CEO, and other
View HTML
Toggle Summary Zynerba Pharmaceuticals to Participate in Upcoming Investor Conferences
DEVON, Pa. , Nov. 24, 2015 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that the Company will participate in the following upcoming
View HTML
Toggle Summary Zynerba Pharmaceuticals to Participate in Upcoming Investor Conferences
DEVON, Pa. , Nov. 09, 2016 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that the Company will participate at various
View HTML
Toggle Summary Zynerba Pharmaceuticals to Participate in Upcoming Investor Meetings and Conferences
DEVON, Pa. , June 01, 2016 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that the Company will participate in various upcoming investor
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at BIO Investor Forum 2015
DEVON, Pa. , Oct. 07, 2015 (GLOBE NEWSWIRE) --   Zynerba Pharmaceuticals , Inc. (NASDAQ:ZYNE), a specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that the company will present at the BIO Investor Forum .
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at 28th Annual ROTH Conference
DEVON, Pa., March 7, 2016 – Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that the Company will present at the 28th Annual ROTH Conference.
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at Canaccord Genuity’s 36th Annual Growth Conference
DEVON, Pa. , Aug. 03, 2016 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that the Company will present at Canaccord Genuity’s
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference
DEVON, Pa. , July 06, 2016 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that the Company will present at Cantor Fitzgerald’s
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at FDA’s Public Hearing on Scientific Data and Information about Products Containing Cannabis or Cannabis-derived Compounds
DEVON, Pa. , May 30, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Ray Mannion , Zynerba’s Vice President of
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at Jefferies Autumn 2015 Global Healthcare Conference
DEVON, Pa. , Nov. 11, 2015 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that the company will present at the Jefferies Autumn 2015 Global
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at Oppenheimer 25th Annual Healthcare Conference
RADNOR, PA – (PR Newswire – November 19, 2014) Zynerba Pharmaceuticals, Inc., a specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that the company will present at the Oppenheimer 25th Annual Healthcare
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2014
RADNOR, PA – (PR Newswire – November 26, 2014) Zynerba Pharmaceuticals, Inc., a specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that the company will present at the Piper Jaffray 26th Annual Healthcare
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at the 2018 BIO Investor Forum
DEVON, Pa. , Oct. 11, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido , Zynerba’s Chief Executive Officer,
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at the 2019 BIO CEO and Investor Conference
DEVON, Pa. , Feb. 05, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Executive Officer, Armando Anido
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference
DEVON, Pa. , Sept. 26, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Executive Officer, Armando Anido
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at the 2019 H.C. Wainwright Global Life Sciences Conference
DEVON, Pa. , April 02, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Executive Officer, Armando Anido
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at the 30th Annual Piper Jaffray Healthcare Conference
DEVON, Pa. , Nov. 20, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Executive Officer, Armando Anido
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at the 38th Annual Canaccord Genuity Growth Conference
DEVON, Pa. , Aug. 01, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Financial Officer, Jim Fickenscher
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at the Cantor Global Healthcare Conference
DEVON, Pa. , Sept. 26, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Executive Officer, Armando Anido
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at the H.C. Wainwright 20th Annual Global Investment Conference
DEVON, Pa. , Aug. 31, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Executive Officer, Armando Anido
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at the Jefferies 2017 Global Healthcare Conference
DEVON, Pa. , June 01, 2017 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative transdermal synthetic cannabinoid treatments, today announced that Zynerba's Chief Financial Officer,
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference
DEVON, Pa. , May 31, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare and near-rare
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at the Jefferies 2019 Global Healthcare Conference
DEVON, Pa. , May 28, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Executive Officer, Armando Anido
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at the Oppenheimer 28th Annual Healthcare Conference
DEVON, Pa. , March 14, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare and near-rare
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at Two Upcoming Conferences
DEVON, Pa. , Sept. 03, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Executive Officer, Armando Anido
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at Two Upcoming Conferences
DEVON, Pa. , July 31, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Executive Officer, Armando Anido
View HTML
Toggle Summary Zynerba Pharmaceuticals to Present at Upcoming Investor Conferences
DEVON, Pa. , Nov. 07, 2017 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments, today announced that Armando Anido ,
View HTML
Toggle Summary Zynerba Pharmaceuticals to Report Fourth Quarter and Full-Year 2016 Financial and Operating Results on March 27, 2017
Conference Call and Webcast Scheduled for 8:30 AM ET DEVON, Pa. , March 13, 2017 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today
View HTML
Toggle Summary Zynerba Provides Clinical Update for Lead Development Candidates – ZYN001 and ZYN002
Phase 1 clinical trial for ZYN001 is expected to begin in 1H17 Topline results for three Phase 2 clinical trials for ZYN002 are on track for 1H17 DEVON, Pa. , Oct. 17, 2016 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated
View HTML
Toggle Summary Zynerba Reports Positive Results for ZYN002 CBD Gel in Phase 1 Studies at 70th Annual Meeting of the American Epilepsy Society
ZYN002 CBD gel was shown to be safe and well-tolerated across range of doses tested in healthy subjects and adult epilepsy patients with focal seizures No impairment in cognitive performance or changes in psychological health were observed DEVON, Pa. , Dec.
View HTML